AzTrials
AzTrials

Rectal NeoplasmsNCT01424293

Fluorescent Evaluation of Colorectal Anastamoses

A study testing Indocyanine Green and The SPY® Intraoperative Imaging System in people with Rectal Neoplasms and Colon Neoplasms, run by Maimonides Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Bowel removal is indicated for various types of colon and rectal disease, including colon cancer, rectal cancer, diverticulitis, and inflammatory bowel disease among others. Following removal of the diseased segment of bowel your surgeon will reconnect the two healthy ends to reconstruct a continuous bowel tube. Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Rectal Neoplasms, Colon Neoplasms, Diverticulitis
What is being tested?
Indocyanine Green and The SPY® Intraoperative Imaging System
Could I receive a placebo?
No, everyone receives an active treatment
How many people
7 participants
Where
1 siteUnited States
Study dates
May 2010to Sep 2016
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Candidates for this study must meet ALL of the following inclusion criteria:
  • Subject is willing and able to provide an informed consent
  • Subject is willing and able to comply with the study procedures
  • Subject speaks English and is able to understand the study procedures
  • A pregnancy test for women of childbearing potential prior to surgery
  • Subject is scheduled for laparoscopic low anterior resection

Who cannot join

  • Candidates for this study who meet any of the following criteria at the time of the baseline visit are NOT eligible to be enrolled in this study:
  • Subject has uremia, serum creatinine >2.5 mg/dl
  • Subject has a previous history of adverse reaction or allergy to ICG, iodine, shellfish or iodine dyes
  • Subjects in whom the use of x-ray dye or ICG is contraindicated including development of adverse events when previously or presently administered
  • Subject has any medical condition, which in the judgment of the Investigator and/or designee makes the subject a poor candidate for the investigational procedure
  • Subject is a pregnant or lactating female
  • Subject is actively participating in another drug, biologic and/or device protocol

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Maimonides Medical Center

    Brooklyn, New York, 11219

Other trials in United States

About this study

Official title: The Use of Fluorescent Imaging to Evaluate Bowel Anastomotic Perfusion

Bowel removal is indicated for various types of colon and rectal disease, including colon cancer, rectal cancer, diverticulitis, and inflammatory bowel disease among others.

Following removal of the diseased segment of bowel your surgeon will reconnect the two healthy ends to reconstruct a continuous bowel tube. If the bowel leaks it can become an extremely dangerous situation.

Read more

The cause of leakage has many causes and is not well understood, but appears to be at least in part due to not having enough blood going to the bowel. There is currently no way to evaluate the blood supply to the bowel.

The purpose of this study is to utilize a special camera to evaluate the blood supply of the bowel. This new system is called the Spy-scope. This system may assist surgeons in reducing the occurrence of leaks

Read the detailed description

The purpose of this study is to evaluate whether systemically injected ICG, when fluorescing in response to NIR illumination, can assist with the assessment of perfusion at a bowel anastomotic site. This finding may assist surgeons to minimize the occurrence of leaks at the anastomotic site following this surgical procedure. The present study is a preliminary investigation to determine if this imaging modality will yield information regarding perfusion that is likely to be clinically relevant and so determine if a larger, multi center trial that correlates perfusion to clinical outcome is warranted. The results of the present study will also assist in the design of a larger scale study. It is expected that a successful outcome to such a trial will result in less morbidity following laparoscopic colectomy.

Laparoscopic bowel surgery is indicated for colon cancer, rectal cancer, diverticulitis, inflammatory bowel disease (including ulcerative colitis or Crohn's disease) and infarcted bowel. Prophylactic colectomy is also indicated for certain forms of polyposis to mitigate the risk of progression to colon cancer. The portion of colon resected during a colectomy is dependent upon the nature of the disease and its location and extent. Traditionally, colectomy has been performed by means of laparotomy, a standard abdominal incision. In recent years, beginning in the early 1990s, there has been increasing interest in, and utilization of, minimally invasive techniques for surgical procedures involving the colon and rectum. Laparoscopic surgery involves the introduction of surgical instruments through a number (usually 2-3) of small incisions measuring about 10-12 mm each with visual guidance being provided by means of a camera attached to an endoscope introduced through a similarly small access port. Laparoscopic techniques offer numerous benefits including a decrease in postoperative pain, some improvement in time to tolerance of food and return of bowel function, shorter hospital stay and more rapid return to normal activity.

Irrespective of the type of procedure performed (open or laparoscopic), anastomotic leakage following colorectal resection and primary anastomosis is a major clinical problem. The incidence of intraperitoneal anastomotic leaks reported in the literature may be as high as 30%. Anastomotic leaks leads to increased length of hospital stay, and may progress to abscess formation, sepsis, multi organ failure and even death.

The cause of anastomotic leakage is multifactorial with the following factors appearing to impact upon leakage; adequacy of blood flow to the anastomosis, contamination, the presence of a pelvic drain, anastomotic tension, anastomotic technique and the distance from the anal verge . The present study will investigate the first factor listed above, adequacy of blood flow to the anastomosis. At present there is no reliable and easy-to-perform modality that can be used to assess adequacy of perfusion at the anastomosis during colorectal procedures. This study will investigate the potential for the SPY scope to fill this clinical need.

The SPY® Intraoperative Imaging System is cleared for use in Canada, Japan, Europe and the US. SPY was originally developed for applications in cardiac surgery and allows cardiac surgeons to visually assess bypass graft quality in real-time while the patient is still in the operating room. Subsequently, SPY has received clearance from the FDA for use in plastic and reconstructive surgery and in solid organ transplant.

The SPY Intraoperative Imaging System was originally developed for open surgical procedures using ICG, which is an approved drug. ICG is a fluorescent compound, which can be administered intravenously or intra-arterially. The dye absorbs light in the near infrared (NIR) region at 806 nm, and emits light at a slightly longer wavelength, 830 nm. When injected intravenously, ICG rapidly and extensively binds to plasma proteins and is confined to the intravascular compartment with minimal leakage into the interstitium under normal conditions. This property makes it an ideal agent for the acquisition of high quality images of the vasculature. Intraoperative images are acquired during the first pass of a bolus of ICG through the area of interest. The SPY System has been the subject of numerous peer reviewed publications demonstrating its safety and efficacy .

SPY scope, the endoscopic version of SPY, is an endoscopic visible (VIS) NIR imaging system consisting of:

  • An endoscopic light source that provides illumination for visible light imaging and NIR fluorescence excitation to the endoscope via a flexible light guide
  • Rigid endoscopes optimized for illuminating the field of view and transmitting images in the visible and NIR spectrum, and
  • A high definition (HD) endoscopic camera system connected to the endoscope eyepiece and acquiring high resolution visible and NIR fluorescence images The ICG (25 mg per vial) will be reconstituted according to the manufacturer's instructions using the entire contents (10 ml) of the sterile diluent supplied, yielding a 2.5 mg/ml solution of ICG or using half of the diluent supplied (5 ml) yielding a 5 mg/ml solution.
Being tested
Indocyanine Green, The SPY® Intraoperative Imaging System
Keywords
Rectal Cancer, Colon Cancer, Diverticulitis, Anastamosis, colectomy, low anterior resection
Medical subject headings
Rectal Neoplasms, Colonic Neoplasms, Diverticulitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Indocyanine GreenDevice

    1ml of intravenous ICG and imaging transanally using the Spyscope system

  • The SPY® Intraoperative Imaging SystemDevice

Study groups in NCT01424293
Study groupRoleWhat they receive
Indocyanine GreenExperimental1ml of intravenous ICG and imaging transanally using the Spyscope system
Receives: Device: Indocyanine Green; Device: The SPY® Intraoperative Imaging System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluate the Vascular Supply of the Bowel Intra-operatively and Correlate This With Postoperative Complications Identified During Their Hospital Stay at One Week and One Month Postoperatively.

    Intra-operative evaluation of bowel perfusion. Participants will be followed for the duration of hospital stay and then at 1 week and 1 month postoperatively to identify postoperative complications.

    Measured: 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Aug 2011 (estimated)
  2. Study startMay 2010
  3. Primary completionSep 2016
  4. Study completionSep 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
7 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01424293
Sponsor's protocol ID
1004va09
Status last verified
Jun 2021
First submitted
29 Sep 2010
Last updated
13 Jul 2021
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Indocyanine Green and The SPY® Intraoperative Imaging System in people with Rectal Neoplasms and Colon Neoplasms, run by Maimonides Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Jul 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluate the Vascular Supply of the Bowel Intra-operatively and Correlate This With Postoperative Complications Identified During Their Hospital Stay at One Week and One Month Postoperatively. (time frame: 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in